{
    "root": "34e9a6b6-450b-7d20-e063-6294a90ac831",
    "code": "34391-3",
    "codeSystem": "2.16.840.1.113883.6.1",
    "displayName": "HUMAN PRESCRIPTION DRUG LABEL",
    "name": "Glimepiride",
    "value": "20250512",
    "ingredients": [
        {
            "name": "LACTOSE MONOHYDRATE",
            "code": "EWQ57Q8I5X"
        },
        {
            "name": "MAGNESIUM STEARATE",
            "code": "70097M6I30"
        },
        {
            "name": "CELLULOSE, MICROCRYSTALLINE",
            "code": "OP1R32D61U"
        },
        {
            "name": "POVIDONE K30",
            "code": "U725QWY32X"
        },
        {
            "name": "SODIUM LAURYL SULFATE",
            "code": "368GB5141J"
        },
        {
            "name": "SODIUM STARCH GLYCOLATE TYPE A POTATO",
            "code": "5856J3G2A2"
        },
        {
            "name": "FERRIC OXIDE RED",
            "code": "1K09F3G675"
        },
        {
            "name": "GLIMEPIRIDE",
            "code": "6KY687524K"
        },
        {
            "name": "FD&C BLUE NO. 2",
            "code": "L06K8R7DQK"
        },
        {
            "name": "FERRIC OXIDE YELLOW",
            "code": "EX438O2MRT"
        }
    ],
    "indications": "Glimepiride tablets are indicated as an adjunct to diet and exercise to improve glycemic control in adults with type 2 diabetes mellitus\n \n  [see\n                     \n                        Clinical Studies (14.1)\n                     \n                     ].\n                  \n                  \n                     \n                        Limitations of Use\n                     \n                      \n                  \n                  \n                  Glimepiride tablets should not be used for the treatment of type 1 diabetes mellitus or diabetic ketoacidosis, as it would not be effective in these settings.",
    "contraindications": "Recommended starting dose is 1 or 2 mg once daily. Increase in 1 or 2 mg increments no more frequently than every 1 to 2 weeks based on glycemic response. Maximum recommended dose is 8 mg once daily. ( 2.1 ) Administer with breakfast or first meal of the day. ( 2.1 ) Use 1 mg starting dose and titrate slowly in patients at increased risk for hypoglycemia (e.g., elderly, patients with renal impairment). ( 2.1 )",
    "warningsAndPrecautions": "Glimepiride Tablets USP are available in the following strengths and package sizes:\n                  \n                  \n                     1 mg (Light pink colored, flat capsule shaped uncoated tablets having break line on both faces and GM and 1 on engraved on either side of breakline on one face.)\n                  \n                  \n                  \n                     Bottles of 100 (NDC 42571-100-01)\n                     Bottles of 500 (NDC 42571-100-05)\n                  \n                  \n                  \n                     2 mg (Light green colored, flat capsule shaped uncoated matt finished tablets having break line on both faces and GM and 2 engraved on either side of breakline on one face.)\n                  \n                  \n                  \n                     Bottles of 100 (NDC 42571-101-01)\n                     Bottles of 500 (NDC 42571-101-05)\n                  \n                  \n                  \n                     3 mg (Pale yellow colored, flat capsule shaped uncoated tablets having breakline on both faces and GM and 3 engraved on either side of breakline on one face.)\n                  \n                  \n                  \n                     Bottles of 100 (NDC 42571-102-01)\n                     Bottles of 500 (NDC 42571-102-05)\n                  \n                  \n                  \n                     4 mg (Light blue colored, flat capsule shaped uncoated matt finished tablets having break line on both faces and GM and 4 engraved on either side of breakline on one face.)\n                  \n                  \n                  \n                     Bottles of 100 (NDC 42571-103-01)\n                     Bottles of 500 (NDC 42571-103-05)\n                  \n                  \n                  \n                     6 mg (Brick red colored, flat capsule shaped uncoated tablets having breakline on both faces and GM and 6 engraved on either side of breakline on one face.)\n                  \n                  \n                  \n                     Bottles of 100 (NDC 42571-104-01)\n                     Bottles of 500 (NDC 42571-104-05)\n                  \n                  \n                  \n                     8 mg (White to off white, flat capsule shaped uncoated tablets having breakline on both faces and GM and 8 engraved on either side of breakline on one face.)\n                  \n                  \n                  \n                     Bottles of 100 (NDC 42571-105-01)\n                     Bottles of 500 (NDC 42571-105-05)\n                  \n                  \n                  Store at 20° to 25°C (68° to 77°F) [see USP Controlled Room Temperature].\n                  \n                  Dispense in well-closed containers with safety closures.",
    "adverseReactions": "Glimepiride tablets are contraindicated in patients with a history of a hypersensitivity reaction to:\n                  \n                  \n                     Glimepiride or any of the product’s ingredients\n  \n   [see\n   \n    Warnings and Precautions (5.2)].\n  \n   \n                     \n                     Sulfonamide derivatives: Patients who have developed an allergic reaction to sulfonamide derivatives may develop an allergic reaction to glimepiride tablets. Do not use glimepiride tablets in patients who have a history of an allergic reaction to sulfonamide derivatives."
}